KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Design of the MERCURION-IPF trial - intravenous immunoglobulin for the treatment of acute exacerbations of idiopathic pulmonary fibrosis.

Vasilina Sotiropoulou, Fotios Sampsonas, Eirini Vasarmidi, Katerina Antoniou, Athena Gogali, Konstantinos Kostikas, Fotios Drakopanagiotakis, Paschalis Steiropoulos, George Margaritopoulos, Konstantinos Porpodis, Zoe Daniil, Ioannis Tomos, Ilias Papanikolaou, Vasilios Tzilas, Stelios Loukides, Argyrios Tzouvelekis

Front Immunol 17 1777564

PMID42164489
PMCIDPMC13183516
DOI10.3389/fimmu.2026.1777564
发表日期2026-05-21
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 1 张 PMC Figure,均未识别为 KM 图:Figure 1:CONSORT/入组流程图。
摘要

摘要

INTRODUCTION: Despite their profound clinical impact and high mortality, acute exacerbations of idiopathic pulmonary fibrosis (AE-IPF) still lack any effective or standardized treatment strategies. This manuscript describes the rationale and design of a randomized, multicenter, open-label Phase III clinical trial evaluating the efficacy of intravenous immunoglobulin (IVIG) compared with usual care in hospitalized patients with AE-IPF. METHODS: This trial will enroll 196 patients across eight different sites in Greece. Inclusion criteria are designed to identify patients with AE-IPF according to the American Thoracic Society definition, while excluding those with cardiac decompensation or pulmonary embolism. The primary endpoint is a composite of all-cause in-hospital mortality or the need for intubation. Secondary endpoints include all-cause mortality at 30 and 90 days, hospital readmission or a new AE-IPF episode within 90 days, and the change in the PaO2/FiO2 ratio from hospital admission to discharge. DISCUSSION: Based on the concept that patients with IPF frequently demonstrate impaired cellular and humoral immunity, and inflammation and/or immune dysregulation may contribute to AE-IPF pathogenesis, there is a strong rationale for evaluating the therapeutic usefulness of IVIG in this setting. Retrospective data indicate that IVIG could provide clinical benefit in AE-IPF, potentially through its anti-inflammatory and immunomodulatory effects. In this trial, IVIG will be administered as an adjunct to usual care, which includes pulse corticosteroids, broad-spectrum antibiotics, prophylactic anticoagulation, and oxygen therapy. This intervention has the potential to significantly influence current treatment strategies for AE-IPF. CLINICAL TRIAL REGISTRATION: https://clinicaltrials.gov/, identifier NCT07299695.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(1,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Study protocol flow diagram.
非 KM Figure